AIM  To analyze and compare the clinical effects and safety of different anticoagulant drugs in the clinical treatment of non-valvular atrial fibrillation (NAVF).

  METHODS  A total of 136 NVAF patients who received anticoagulant therapy from April 2018 to April 2021 were selected. Among them, 76 patients were treated with rivaroxaban anticoagulant therapy in group L and 60 patients were treated with dabigatran etexilate in group D. Coagulation, improvement of blood routine indexes, bleeding and adverse events were analyzed and compared between the two groups after three months of medication.

  RESULTS  Three months after the treatment, the platelets of the two groups increased significantly compared with those before the treatment (P<0.05). The red blood cell and prothrombin time in L group after treatment was significantly higher than those of that before treatment (P<0.05). After the medication, there was no significant difference between group L and group D. The total incidence of bleeding during medication in group L was 34.21%, which was significantly higher than that of the rate of 11.67% in group D (P<0.01). The total incidence of adverse events in group L was 22.37 % compared with 21.67 % in group D, and there was no statistical difference in both of those.

  CONCLUSION  Both rivaroxaban and dabigatran etexilate achieve ideal clinical efficacy in patients with NVAF, but the lsafety factor of dabigatran etexilate is higher.